Patents Issued in October 12, 2004
-
Patent number: 6803355Abstract: Detergent compositions are formulated with a mixture of hydrophobically modified cellulose polymers or oligomers and cyclic amine based polymers or oligomers. The cellulose/amine mixture maintains the integrity and appearance of fabrics laundered in the compositions. Dye maintenance and anti-pilling benefits are provided. The compositions are provided in containers which alert the user of the benefits provided by the compositions.Type: GrantFiled: August 3, 2001Date of Patent: October 12, 2004Assignee: The Procter & Gamble CompanyInventors: Rajan Keshav Panandiker, Jennifer Leupin Moe, William Conrad Wertz
-
Patent number: 6803356Abstract: A method for the preparation of polymers derived from acrolein and including poly(2-propenal, 2-propenoic acid), characterised in that the polymers are exposed to the presence of water, whereby such polymers exhibit increased antimicrobial activity. The polymers may be heated in the range of 40 to 150° C. Further, the polymers may be prepared in the presence of polyethylene glycols, polyols and/or alkanols.Type: GrantFiled: November 8, 2001Date of Patent: October 12, 2004Assignee: Chemeq Ltd.Inventors: Graham John Hamilton Melrose, Gerry Daly, Andrew James Huxham
-
Patent number: 6803357Abstract: The present invention provides methods and compositions for modification and regulation of GLP 1 metabolism, glucose and lipid metabolism, generally to reduce insulin resistance, hyperglycemia, hyperinsulinemia, obesity, hyperlipidemia, hyperlipoproteinemia (such as chylomicrons, VLDL and LDL), and to regulate body fat and more generally lipid stores, and, more generally, for the improvement of metabolism disorders, especially those associated with diabetes, obesity and/or atherosclerosis. The compositions described herein are high-affinity boronyl and non-boronyl peptidomimetic inhibitors of DPIV.Type: GrantFiled: January 5, 2001Date of Patent: October 12, 2004Assignees: New England Medical Center Hospitals, Inc., Trustees of Tufts College, 1149336 Ontario Inc.Inventors: William A. Bachovchin, Andrew G. Plaut, Daniel Drucker
-
Patent number: 6803358Abstract: The present invention provides a protein having an A chain of a ricin-like toxin, a B chain of a ricin-like toxin and a heterologous linker amino acid sequence, linking the A and B chains. The linker sequence contains a cleavage recognition site for a disease specific protease such as a cancer, fungal, viral or parasitic protease. The invention also relates to a nucleic acid molecule encoding the protein and to expression vectors incorporating the nucleic acid molecule. Also provided is a method of inhibiting or destroying mammalian cancer cells, cells infected with a virus, a fugus, or parasites, or parasites utilizing the nucleic acid molecules and proteins of the invention and pharmaceutical compositions for treating human cancer, viral infection, fugal infection, or parasitic infection.Type: GrantFiled: April 14, 2000Date of Patent: October 12, 2004Assignee: Twinstrand Therapeutics Inc.Inventor: Thor Borgford
-
Patent number: 6803359Abstract: The glutamic acid residue of corticotropin-releasing hormone analogs have had the position 20 amino acid residue replaced with a D-amino acid moiety. The resulting CRH analogs do not significantly lower blood pressure but have anti-proliferative actions in cell culture and inhibit experimental cancer growth in animals (mice and rats). Novel applications of such analogs are described, such as to inhibit abnormal cell proliferation for conditions such as cancer, including melanoma, and for inflammatory dermatoses, such as psoriasis.Type: GrantFiled: November 19, 2001Date of Patent: October 12, 2004Assignees: The Regents of the University of California, Loyola University of ChicagoInventors: Edward T. Wei, Andrzej T. Slominski
-
Patent number: 6803360Abstract: Provided are antisense oligonucleotides directed against the raf-1 gene, Ha-ras gene and HER-2 gene, components of a signal transduction pathway involving oncogenes and their normal counterparts and leading to the phenotype of cellular radioresistance. Administration of these antisense oligonucleotides is shown to reverse the radioresistance phenotype in cells overexpressing HER-2 or a mutant form of Ha-ras. Methods and compositions for reversing radiation resisting among other conditions involving these genes are disclosed.Type: GrantFiled: November 21, 2000Date of Patent: October 12, 2004Assignee: Georgetown UniversityInventors: Esther H. Chang, Kathleen F. Pirollo
-
Patent number: 6803361Abstract: Disclosed and claimed is the use of a liquid jet intradermal administration apparatus that administers a composition: without a needle; and in the epidermis, dermis and/or hypodermis, such as a Pigjet apparatus, for administering bovine vaccines or immunogenic compositions, especially bovine plasmid vaccines or immunogenic compositions. Accordingly, the invention involves bovine immunogenic or vaccine compositions in such an apparatus, and methods for vaccinating bovines or for inducing an immunogenic response in bovines employing such an apparatus, as well as the apparatus containing bovine immunogenic or vaccine compositions.Type: GrantFiled: February 15, 2002Date of Patent: October 12, 2004Inventors: Franciscus Antonius Maria Rijsewijk, Remco Siebren Schrijver, Johannes Theodorus Van Oirschot
-
Patent number: 6803362Abstract: Heterocyclic compounds and methods of making them and using them.Type: GrantFiled: March 8, 2002Date of Patent: October 12, 2004Assignee: Ortho-McNeil Pharmaceutical inc.Inventors: Nicholas I. Carruthers, Wenying Chai, Curt A. Dvorak, James P. Edwards, Cheryl A. Grice, Jill A. Jablonowski, Lars Karlsson, Haripada Khatuya, Jennifer D. Kreisberg, Annette K. Kwok, Timothy W. Lovenberg, Kiev S. Ly, Barbara Pio, Chandravadan R. Shah, Siguan Sun, Robin L. Thurmond, Jianmei Wei, Wei Xiao
-
Patent number: 6803363Abstract: The present invention contemplates the addition of 0.5% to 4% taurolidine into solutions used peritoneal dialysis. The taurolidine is intended to prevent or reduce the incidence of infection within the abdomen and/or in the vicinity of an implanted dialysis port. The invention also includes methods using solutions of taurolidine in the flushing and locking of catheters and fluid lines used in peritoneal dialysis.Type: GrantFiled: May 31, 2002Date of Patent: October 12, 2004Assignee: ND Partners, LLCInventor: Hans-Dietrich Polaschegg
-
Patent number: 6803364Abstract: The present invention is concerned with the compounds of formula (I), a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein p is 0 to 4; q is 0 to 5; X is O, S, NR3 or a direct bond; or —X—R2 is CN; R1 is H, OH, halo, NH2, mono- or di(C1-4alkyl)NH2, C1-6alkyl, C1-6alkylO, C3-7cycloalkyl, aryl, arylC1-6alkyl, NH2C1-4akyl, mono- or di(C1-4alkyl)NH2C1-4akyl or mono- or di(C1-4alkyl)NH2C1-4alkylNH2; R2 is aryl, Het1, optionally substituted C3-7cycloalkyl, optionally substituted C1-6alkyl; R3 is H or C1-4alkyl; R4 and R5 are —C(═O)—Z—R14, C1-6alkyl, halo, polyhaloC1-6alkyl, OH, mercapto, C1-6alkylO, C1-6alkylthio, C1-6alkylC(═O)O, aryl, cyano, nitro, Het3, R6, NR7R8 or C1-4alkyl substituted with —C(═O)—Z—R14, Het3, R6 or NR7R8; Z is O, S, NH, —CH2O or —CH2—S—; R14 is H, C1-20acyl, optionally substituted C1-20alkyl, optionally substituted C3-20alkenyl, C3-2Type: GrantFiled: August 29, 2001Date of Patent: October 12, 2004Assignee: Janssen Pharmaceutica N.V.Inventors: Eddy Jean Edgard Freyne, Frederik Dirk Deroose, Jean Fernand Armand Lacrampe, Werner Constant Johan Embrechts, Jerome Michel Claude Fortin
-
Patent number: 6803365Abstract: The invention relates to imidazo[1.3.5]triazinones, a method for their production and methods of use, in particular as inhibitors of cyclic GMP metabolizing phosphodiesterases.Type: GrantFiled: November 4, 2002Date of Patent: October 12, 2004Assignee: Bayer AktlengesellschaftInventors: Ulrich Niewöhner, Helmut Haning, Thomas Lampe, Mazen Es-Sayed, Gunter Schmidt, Erwin Bischoff, Klaus Dembowsky, Elisabeth Perzborn, Karl-Heinz Schlemmer
-
Patent number: 6803366Abstract: Disclosed is an agent for improving learning and/or memory, which is useful for therapy of dementia accompanying disorder of memory due to a cerebrovascular disease, neurodegenerative disease such as Alzheimer's disease, endocrine disease, nutritional or metabolic disorder, infectious disease, drug addiction or the like. The agent for improving learning and/or memory according to the present invention comprises as an effective ingredient an isoquinoline derivative having a specific structure, such as (4aR, 12aR)-2-methyl-4a-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12a-octahydro-quinoline[2,3-g]isoquinoline or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 30, 2002Date of Patent: October 12, 2004Assignee: Toray Industries, Inc.Inventors: Kuniaki Kawamura, Hiroshi Nagase, Noriyuki Hirano, Junzo Kamei
-
Patent number: 6803367Abstract: A substance for inducing apoptosis represented by specific formulae. A pharmaceutical composition which can be used for an anticancer agent containing said substance.Type: GrantFiled: October 1, 2002Date of Patent: October 12, 2004Assignee: Takara Shuzo Co., Ltd.Inventors: Tatsuji Enoki, Nobuto Koyama, Katsushige Ikai, Ikunoshin Kato
-
Patent number: 6803368Abstract: Compounds of the formula useful for treatment of disorders of the dopaminergic system, such as schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L-DOPA induced pychoses and dyskinesias, Tourette's syndrome and hyperprolactinemia and in the treatment of drug addiction such as the addiction to ethanol, nicotine or cocaine and related illnesses.Type: GrantFiled: April 23, 2002Date of Patent: October 12, 2004Assignee: WyethInventors: Gary P. Stack, James A. Nelson
-
Patent number: 6803369Abstract: A method of modulating the activity of a aberrant cell topoisomerase enzyme involving contacting the enzyme with a compound that inhibits enzyme-mediated cleavage of a polynucleotide substrate with which the enzyme is in complex. Pharmaceutical compositions containing such compounds may be used to treat neoplasias or to inhibit the growth of certain cancer cells. Screening methods can be employed to identify other compounds for these uses.Type: GrantFiled: July 25, 2001Date of Patent: October 12, 2004Assignees: SmithKline Beecham Corporation, SmithKlineBeecham p.l.c.Inventors: Symon G. Erskine, Michael Gwynn, Neil David Pearson, Edwina Imogen Wilding
-
Patent number: 6803370Abstract: Disclosed are certain alpha amino acid compounds which bind VLA-4. Certain of these compounds also inhibit leukocyte adhesion and, in particular, leukocyte adhesion mediated by VLA-4. Such compounds are useful in the treatment of inflammatory diseases in a mammalian patient, e.g., human, such as asthma, Alzheimer's disease, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, tissue transplantation, tumor metastasis and myocardial ischemia. The compounds can also be administered for the treatment of inflammatory brain diseases such as multiple sclerosis.Type: GrantFiled: July 20, 2001Date of Patent: October 12, 2004Assignees: Elan Pharmaceuticals, Inc., WyethInventors: Andrei W. Konradi, Michael A. Pleiss, Eugene D. Thorsett, Susan Ashwell, Gregory S. Welmaker, Anthony Kreft, Dimitrios Sarantakis, Darren B. Dressen, Francine S. Grant, Christopher Semko, Ying-Zi Xu
-
Patent number: 6803371Abstract: The present invention relates to 2-N-substituted 6-(4-methoxybenzylamino)-9-isopropylpurines that inhibit, inter alia, protein kinases, G-proteins and polymerases. In addition, the present invention relates to methods of using such 2-N-substituted 6-(4-methoxybenzylamino)-9-isopropylpurines to inhibit protein kinases, G-proteins, polymerases and other cellular processes and to treat cellular proliferative diseases.Type: GrantFiled: January 27, 2003Date of Patent: October 12, 2004Assignees: The Regents of the University of California, Centre National de la RechercheInventors: Nathanael S. Gray, Peter Schultz, Sung-Hou Kim, Laurent Meijer
-
Patent number: 6803372Abstract: Compounds of the general formula (I): wherein Ar1 represents optionally substituted aryl or heteroaryl; n represents 0 or 1; T, U, V, and W each independently represent nitrogen atom or optionally substituted methine group, where at least two of them represent the said methine group; X represents methine or hydroxy substituted methine; Y represents an optionally substituted imino or oxygen atom are described and claimed. These novel spiro compounds are useful as neuropeptide Y receptor antagonists and as agents for the treatment of various kinds of cardiovascular disorders, central nervous system disorders, metabolic diseases and the like.Type: GrantFiled: March 8, 2002Date of Patent: October 12, 2004Assignee: Banyu Pharmaceutical Co., Ltd.Inventors: Takehiro Fukami, Akio Kanatani, Akane Ishihara, Yasuyuki Ishii, Toshiyuki Takahashi, Yuji Haga, Toshihiro Sakamoto, Takahiro Itoh
-
Patent number: 6803373Abstract: A combination of 9,10-dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7,-dimethoxy-2-isoquinolinyl)ethyl]pheny]-4-acridinecarboxamide or a salt thereof and paclitaxel and its analogs or derivatives.Type: GrantFiled: September 3, 2002Date of Patent: October 12, 2004Assignee: SmithKline Beecham CorporationInventor: Jan H. M. Schellens
-
Patent number: 6803374Abstract: A series of compounds of Formula I are disclosed which are useful in treating viral hepatitus C.Type: GrantFiled: August 27, 2003Date of Patent: October 12, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Eldon Scott Priestley, Carl P. Decicco, Thomas W. Hudyma, Xiaofan Zheng
-
Patent number: 6803375Abstract: Compounds, preparations and methods for immunosuppressive treatment of autoimmune disorders, graft rejection and/or graft/host disease. Therapeutically effective amounts of certain substituted triarylmethane compounds, such as 1-[(2-chlorophenyl)diphenylmethyl]-1H-pyrazole, are administered to mammalian patients to selectively inhibit the calcium-activated K+ channel (IKCa1) in lymphocytes, monocytes, macrophages, platelets or endothelial cells without concomitant inhibition of P450-dependent enzyme systems, resulting in reduction of antigen-, cytokine-, or mitogen-induced calcium entry through store operated calcium channels in these cells, suppression of cytokine production by these cells, and inhibition of activation of these cells. Such inhibition of the Ca++ activated K+ channel (IKCa1) prevents the pre-Ca++ stage of cell activation and thus causes immunosuppression and an anti-inflammatory response.Type: GrantFiled: January 6, 2000Date of Patent: October 12, 2004Assignee: The Regents of the University of CaliforniaInventors: K. George Chandy, Heike Wulff
-
Patent number: 6803376Abstract: This invention relates, in part, to newly identified methods of using quinolone antibiotics, particularly a gemifloxacin compound against certain pathogenic bacteria, particularly quinolone resistant S. pnemoniae and rare H. influenzae strains.Type: GrantFiled: May 12, 2000Date of Patent: October 12, 2004Assignee: SmithKline Beecham CorporationInventors: Peter C. Appelbaum, Kim L. Credito, Todd Davies, Diane B. Hoellman, Linda M. Kelly, Glenn A. Pankuch
-
Patent number: 6803377Abstract: The present invention provides compositions for controlling plant pests, containing the compound of the formula (I) and at least one fungicidally active compound, except for tebuconazole, cyclopropylcarboxamides and azolylmethylcycloalkanes.Type: GrantFiled: June 26, 2002Date of Patent: October 12, 2004Assignee: Bayer AktiengesellschaftInventors: Christoph Erdelen, Wolfram Andersch, Klaus Stenzel, Astrid Mauler-Machnik, Wolfgang Krämer
-
Patent number: 6803378Abstract: Novel diketoacid compounds of Formula I are provided which are useful as HIV integrase inhibitors and for the treatment of AIDS or ARC.Type: GrantFiled: September 25, 2002Date of Patent: October 12, 2004Assignee: Bristol-Myers Squibb CompanyInventors: Michael A. Walker, Timothy D. Johnson, Nicholas A. Meanwell, Jacque Banville
-
Patent number: 6803379Abstract: The invention relates to the treatment of viral, bacterial, parasitic, proliferative diseases, neurodegenerative diseases, inflammatory diseases, immunological diseases, transplanted organ rejection, and diseases produced by intoxication with heavy metals. The invention relates to the use of specific metal chelating agents including, furoic acid, 2-thiophenecarboxylic acid and their derivatives, analogs and structurally related chemicals as pharmacological agents that can be used effectively to disrupt and inactivate specific transition metal ion containing zinc finger structural motifs in metalloproteins and specific transition metal ion containing catalytic sites in metalloproteinases, which in turn, inactivate the pathogenic virus, pathogenic prokaryotic or eukaryotic cells which produces disease conditions. The preparations can be administered topically or for systemic use.Type: GrantFiled: June 4, 2002Date of Patent: October 12, 2004Inventors: Jose A. Fernandez-Pol, Sebastian Fernandez-Pol
-
Patent number: 6803380Abstract: 5-aryl-1H-triazole compounds of the formula are potent and selective COX-2 inhibitors. The invention further relates to pharmaceutical compositions containing these compounds.Type: GrantFiled: May 17, 2002Date of Patent: October 12, 2004Assignee: Laboratoire TheramexInventors: Jean-Claude Pascal, Denis Carniato
-
Patent number: 6803381Abstract: The present invention relates to compounds of formula wherein R1 is hydrogen or lower alkyl; R2, R2′ are each independently hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl; X is O, S or two hydrogen atoms not forming a bridge; A1/A2 is phenyl; B is a group of formula wherein R3 is lower alkyl, lower alkenyl, lower alkinyl, benzyl, lower alkyl-cycloalkyl, lower alkyl-cyano, lower alkyl-pyridinyl, lower alkyl-lower alkoxy-phenyl, lower alkyl-phenyl, which is optionally substituted by lower alkoxy, or phenyl, which is optionally substituted by lower alkoxy, or lower alkyl-thienyl, cycloalkyl, lower alkyl-trifluoromethyl or lower alkyl-morpholinyl; Y is —O—, —S— or a bond; and Z is —O—; or a pharmaceutically acceptable salt thereof. These compounds are useful for the control or prevention of acute and/or chronic neurological disorders.Type: GrantFiled: May 14, 2003Date of Patent: October 12, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Konrad Bleicher, Vincent Mutel, Eric Vieira, Jürgen Wichmann, Thomas Johannes Woltering
-
Patent number: 6803382Abstract: The invention relates to novel 1-oxaspiro[2,5]octan-6-ol derivatives of general formula (I): and also to a method for preparing them, and to their use in pharmaceutical compositions for use in human or veterinary medicine, or in cosmetic compositions.Type: GrantFiled: November 8, 2002Date of Patent: October 12, 2004Assignee: Galderma Research & Development, S.N.C.Inventors: Jacques Eustache, Jean-Guy Boiteau, Céline Tarnus, Vincent Rodeschini, Pierre Van De Weghe
-
Patent number: 6803383Abstract: Compounds which inhibit tumor growth and angiogenesis, of general formula (II) are provided. These compounds include glycyl lysine derivatives bound to a central aromatic linking core.Type: GrantFiled: September 27, 2002Date of Patent: October 12, 2004Assignee: The Scripps Research InstituteInventors: Dale L. Boger, David A. Cheresh
-
Patent number: 6803384Abstract: A compound of formula Id and pharmaceutically acceptable salts and esters thereof, wherein the substituent designations are as provided in the specification. Compounds of the invention are useful for treating reperfusion injury.Type: GrantFiled: January 22, 2003Date of Patent: October 12, 2004Assignee: Hoffmann-La Roche Inc.Inventors: Nader Fotouhi, Paul Gillespie, Robert William Guthrie, Sherrie Lynn Pietranico-Cole, Weiya Yun
-
Patent number: 6803385Abstract: Hydroxyeicosatetraenoic acid esters and methods of their use in treating dry eye disorders are disclosed.Type: GrantFiled: April 4, 2003Date of Patent: October 12, 2004Assignee: Alcon, Inc.Inventors: Peter G. Klimko, Mark R. Hellberg, John R. Falck, Raymond E. Conrow
-
Patent number: 6803386Abstract: The present invention is directed to a pharmaceutical composition containing a cancer-treating effective amount of a class of prostacyclin derivatives, and a pharmaceutically acceptable carrier, and to kits and methods of employing the same for the treatment of cancer.Type: GrantFiled: January 16, 2002Date of Patent: October 12, 2004Assignee: United Therapeutics CorporationInventors: Robert Shorr, Martine Rothblatt
-
Patent number: 6803387Abstract: A compound of formula I or a pharmaceutically acceptable salt thereof in which R1 and R2 are independently H or methyl (for example N,N-dimethyl-1-[1-(4-chlorophenyl) cyclobutyl]-3-methylbutyl amine hydrochloride optionally in the form of its monohydrate) is used for treating fibromyalgia or neuropathic pain, such as pain associated with diabetes mellitus, shingles, nerve injury and varied peripheral neuropathies.Type: GrantFiled: March 17, 2000Date of Patent: October 12, 2004Assignee: Abbott GmbH & Co. KGInventors: Carl M. Mendel, Timothy B. Seaton, Steve P. Weinstein, Edward Chong
-
Patent number: 6803388Abstract: The invention relates to substituted aryl and heteroaryl (R)-Chiral Halogenated 1-Substitutedamino-(n+1)-Alkanol compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Novel high yield, stereoselective processes for the preparation of the chiral substituted alkanol compounds from chiral and achiral intermediates are described. Preferred (R)-Chiral 1-Substitutedamino-(n+1)-Alkanol compounds are substituted (R)-Chiral N,N-bis-phenyl aminoalcohols. A preferred specific (R)-Chiral N,N-bis phenyl aminoclcohol is the compound.Type: GrantFiled: December 12, 2001Date of Patent: October 12, 2004Assignee: Pfizer, Inc.Inventors: James A. Sikorski, Richard C. Durley, Margaret L. Grapperhaus, Mark A. Massa, Emily J. Reinhard, Yvette M. Fobian, Michael B. Tollefson, Lijuan Wang, Brian S. Hickory, Monica B. Norton, William F. Vernier, Deborah A. Mischke, Michele A. Promo, Ashton T. Hamme, Dale P. Spangler, Melvin L. Rueppel
-
Patent number: 6803389Abstract: This invention discloses a process for producing a polyester resin, which is transparent, substantially free of occurrence of foreign matters or filtration residue, and is subject to no problem in physical properties, within short time, by concurrently reacting polyester whose chief starting material is terephthalic acid and which has been recovered from waste materials and regenerated; a polyhydric alcohol component and a polybasic acid component, at such ratios that the regenerated polyester occupies 10-80% by weight based on the total weight of the regenerated polyester, polyhydric alcohol component and polybasic acid component.Type: GrantFiled: August 13, 2001Date of Patent: October 12, 2004Assignee: Kansai Paint Co., Ltd.Inventors: Chicara Kawamura, Isamu Takabayashi
-
Patent number: 6803390Abstract: Polyurethane foams are made using a prepolymer that is the reaction product of an organic polyisocyanate, a hydroxy-functional acrylate or methacrylate, and a polyol. This prepolymer is reacted at specified volume ratios and isocyanate indices with a polyol component that includes at least one polyol. The foam is made in the presence of a blowing agent and catalyst. Preferred blowing agents are water and chemical blowing agents that generate carbon dioxide in the reaction. Preferred catalysts have primary or secondary amine groups that allow them to react into the resulting polymer structure, thus decreasing the level of volatile components.Type: GrantFiled: March 29, 2002Date of Patent: October 12, 2004Assignee: Dow Global Technologies Inc.Inventors: Huzeir Lekovic, Ali J. El-Khatib, Frank V. Billotto
-
Patent number: 6803391Abstract: Ethylene copolymer elastomer compositions, acrylate rubber compositions, nitrile rubber compositions, fluoroelastomer compositions, and chlorinated olefin elastomer compositions are provided which are curable by exposure to UV radiation. The compositions are particularly suited for production of elastomeric seals using hot melt equipment and a gasketing in place technique.Type: GrantFiled: September 20, 2002Date of Patent: October 12, 2004Assignee: DuPont Dow Elastomers, LLCInventors: Patrick Luigi Paglia, Christian Ruepping
-
Patent number: 6803392Abstract: Aqueous storage-stable, non-sedimenting photoinitiator suspensions comprising (a) a mono- or bis-acylphosphine oxide of formula (I), wherein R1 is C1-C20alkyl; C2-C20alkyl interrupted by one or more O atoms; C1-C12alkoxy; phenyl-C1-C4alkyl; or phenyl that is unsubstituted or substituted by C1C20alkyl, C1-C12alkoxy, halogen, cyclopentyl, cyclohexyl, C2-C12alkenyl, C2-C18alkyl interrupted by one or more O atoms, and/or by phenyl-C1-C4alkyl; or R1 is biphenylyl; R2 is an aromatic radical or has one of the meanings give for R1; R3 and R4 are each independently of the other C1-C12alkyl, C1-C12alkoxy or halogen; and R5 is hydrogen, C1-C12alkyl, C1-C12alkoxy or halogen; (b) a dispersant; and (c) water are suitable especially in the photopolymerisation of aqueous formulations comprising ethylenically unsaturated monomers.Type: GrantFiled: March 18, 2002Date of Patent: October 12, 2004Assignee: Ciba Specialty Chemicals CorporationInventors: Manfred Köhler, Beat Michael Aebli, Martin Holer, Ernst Eckstein, Jean-Pierre Wolf
-
Patent number: 6803393Abstract: Multicomponent system curable thermally and with actinic radiation, comprising A) an isocyanate-reactive binder comprising A1) at least one unsaturated polyester whose molecule contains on average at least one group that can be activated with actinic radiation, of the formulae I, II and/or III wherein n is an integer from 1 to 10; and A2) at least one binder, different than (A1), whose molecule comprises on average at least two isocyanate-reactive functional groups, and/or A3) at least one binder, different than (A1), whose molecule comprises on average at least one isocyanate-reactive functional group and at least one reactive functional group having at least one bond that can be activated with actinic radiation, and B) a crosslinker comprising B1) at least one polyisocyanate and/or B2) at least one polyisocyanate whose molecule comprises on average at least one reactive functional group having at least one bond that can be activated with actinic radiation.Type: GrantFiled: December 11, 2002Date of Patent: October 12, 2004Assignee: BASF Coatings AGInventors: Rainer Blum, Maxime Allard
-
Patent number: 6803394Abstract: A composition for actinic radiation curable nail coatings and artificial nail tips comprising a BISGMA based urethane resin, an additional polymer, a photoinitiator, and having a viscosity of greater than approximately 80,000 cps. Composition may additionally comprise other additives known in the art and also methods of application of the composition alone and with related compositions.Type: GrantFiled: May 21, 2002Date of Patent: October 12, 2004Assignee: Gel Products, Inc.Inventors: Pamela H. Lilley, Sarah Peterson
-
Patent number: 6803395Abstract: Disclosed is an ink composition which comprises water, a colorant, and a lightfastness agent which is a polysiloxane having thereon a hydrophilic moiety and a lightfastness moiety. Also disclosed are printing processes using the ink.Type: GrantFiled: November 15, 2001Date of Patent: October 12, 2004Assignee: Xerox CorporationInventors: Thomas W. Smith, Kathleen M. McGrane
-
Patent number: 6803396Abstract: Aqueous superplasticizer solutions for concrete compositions include a polymeric superplasticizer and an air-detraining effective amount of a block polyether containing ethylene oxide and propylene oxide units.Type: GrantFiled: August 16, 2001Date of Patent: October 12, 2004Assignee: BASF CorporationInventors: Sridhar Gopalkrishnan, Kenneth L. Zack, Karl-Heinz Buechner
-
Patent number: 6803397Abstract: A thermoplastic molding composition containing a (co)polymer of vinylcyclohexane and a stabilizer system is disclosed. The stabilizer system contains lactone, sterically hindered phenol and a phosphite compound. The composition that is characterized by its improved thermal stability is suitable for the preparation of molded articles, including optical data carriers.Type: GrantFiled: August 16, 2001Date of Patent: October 12, 2004Assignee: Bayer AktiengesellschaftInventors: Volker Wege, Konstadinos Douzinas, Friedrich-Karl Bruder
-
Patent number: 6803398Abstract: An olefin-based thermoplastic elastomer composition comprising a thermoplastic elastomer blended with other resins and rubbers is provided. The thermoplastic elastomer contains polypropylene resin and an olefin-based copolymer rubber, and optionally, a linear polyethylene resin, and the thermoplastic elastomer has been crosslinked to a gel content of 95% or higher. A polyolefin resin, an olefin-based copolymer rubber and a softening agent are further blended with optional inorganic filler to provide the olefin-based thermoplastic elastomer composition. This composition is excellent in oil resistance and extrudability, and well-adapted for use as an energy-saving, resources-saving elastomer in applications including surface or skin material in autoparts, industrial mechanical parts, electric and electronic parts, and construction materials.Type: GrantFiled: February 28, 2000Date of Patent: October 12, 2004Assignees: Mitsui Chemicals, Inc., Toyota Motor CorporationInventors: Yuichi Ito, Hiroyasu Yamaoka, Akira Uchiyama, Chika Kako, Hideo Nishimura, Junzo Ukai
-
Patent number: 6803399Abstract: Silicone liquid crystals, silicone vesicles, and silicone gels are formed by combining (i) an amine functional silicone or an organic amine compound, (ii) an organic epoxide containing at least two epoxy groups or an epoxy functional silicone containing at least two epoxy groups, and (iii) a fluid such as water, a silicone fluid other than a silicone used in (i) and (ii), and a polar organic compound or nonpolar organic compound other than organic compounds used in (i) and (ii) in which the polar and nonpolar organic compound are present at a concentration to provide a level of solids less than 40 percent by weight based on the weight of (i)-(iii). These silicone liquid crystals, silicone vesicles, and silicone gels are useful in personal care for preparing various skin, hair, and underarm products.Type: GrantFiled: June 19, 2003Date of Patent: October 12, 2004Assignee: Dow Corning CorporationInventors: Michael Salvatore Ferritto, Zuchen Lin, William James Schulz, Jr.
-
Patent number: 6803400Abstract: Water-swellable hot-melt adhesives based on a tackifying resin, a water-dispersible EVA wax, an ethylene/acrylic ester copolymer, a water-soluble homo- or co-polymer and a super absorber polymer powder having an average particle size of less than 80 &mgr;m display a clearly improved swelling behavior in comparison with the prior art. Furthermore, the swelling agent is significantly more homogeneously distributed in the matrix. Such hot-melt adhesives are suitable for ensuring longitudinal water impermeability in modern cable structures, as water-swellable jointing compounds in the building industry in the area of building conservation and restoration. Such hot-melt adhesives are further suitable for the manufacture of absorbent textile fabrics in the personal hygiene sector.Type: GrantFiled: March 30, 2001Date of Patent: October 12, 2004Assignee: Henkel Kommanditgesellschaft auf AktienInventors: Ruediger Butterbach, Ulricke Maassen, Siegfried Kopannia
-
Patent number: 6803401Abstract: A halogen scavenging system is provided for inhibiting the corrosion-causing tendency and coloration of halogen-containing olefin polymers or copolymers, comprising incorporating about 0.01% to about 1% of a hydroltalcite-like solid solution having the formula Al2(Mg)a(OH)b(CO3)c(G)d.eH2O and a crystallite size in the <003> direction of about 190 Å to about 225 Å, and having bidentate coordination for carbonate ion as shown by an infrared spectrum, and wherein 3≦a≦5.5; 8≦b≦14; 1.2≦c≦3; 0≦d≦1; 1≦e≦10 and G is a surface active agent into the halogen containing olefin polymer.Type: GrantFiled: September 21, 2001Date of Patent: October 12, 2004Assignee: Reheis, Inc.Inventors: Jawahar C. Parekh, Rajanikant D. Desai
-
Patent number: 6803402Abstract: Elastomer molded article for semiconductor production apparatuses which is obtained by crosslinking and molding a crosslinkable fluorine-containing elastomer composition comprising a crosslinkable fluorine-containing elastomer component and fine particles of aluminum oxide having an average particle size of not more than 0.5 &mgr;m. The elastomer molded article is excellent in plasma resistance and an amount of micro particles generated after irradiation of plasma is very small and therefore a very clean molded article for semiconductor production apparatuses, particularly a sealing material to be used in an environment of plasma irradiation is provided.Type: GrantFiled: October 29, 2001Date of Patent: October 12, 2004Assignee: Daikin Industries, Ltd.Inventors: Katsuhiko Higashino, Masanori Hasegawa, Hiroyuki Tanaka, Tsuyoshi Noguchi
-
Patent number: 6803403Abstract: A polymer emulsion with good film forming property, which is mixed a synthetic polymer emulsion containing the polymer having the particle size of 0.15 &mgr;m or longer in diameter and a synthetic polymer emulsion containing the polymer having particle size of 0.10 &mgr;m or shorter in diameter, wherein the glass transition temperature of the latter polymer is at least 20 degree lower than that of the former emulsion and the particle size ratio between the former polymer and the latter polymer is 2 or more. The polymer emulsion is used for making moisture-proof coated paper and/or recyclable-coated paper.Type: GrantFiled: February 28, 2002Date of Patent: October 12, 2004Assignee: Shinto Fine Co., Ltd.Inventor: Takamasa Ishihara
-
Patent number: 6803405Abstract: The invention relates to the aqueous preparation of a polymer. Said preparation contains a copolymer consisting of a) 30 to 79.5 wt. % N-vinylpyrrolidone, b) 20 to 69.5 wt. % vinylacetate, c) 0.5 to 25 wt % of a monovinyl ester of a C4 to C20 monocarboxylic acid and d) 0 to 40 wt. % of an additional, copolymerisable, ethylenically unsaturated compound.Type: GrantFiled: March 29, 2002Date of Patent: October 12, 2004Assignee: BASF AktiengesellschaftInventors: Klaus Schnell, Michael Kerber, Eberhard Schupp, Eckehardt Wistuba